<DOC>
	<DOCNO>NCT00561834</DOCNO>
	<brief_summary>The purpose study explore safety efficacy ranibizumab treat non-arteritic ischemic optic neuropathy base clinical anatomical finding .</brief_summary>
	<brief_title>Ranibizumab Therapy Non-arteritic Ischemic Optic Neuropathy</brief_title>
	<detailed_description>Nonarteritic anterior ischemic optic neuropathy ( NAION ) common acute optic neuropathy people older 50 year . It characterize sudden partial loss vision one eye increase risk vision loss fellow eye . Although cause determine , NAION think occur follow idiopathic ischemic event involve short posterior ciliary artery supply blood anterior part optic nerve . A complete loss vision rare , partial loss visual field acuity result NAION affect eye ( ) . Patients 'disc risk ' 'crowded disc ' ( small cup : disc ratio ) increase risk develop NAION . Other risk factor NAION include age &gt; 50 year white race ( estimate 95 % case ) . Hypertension diabetes also predispose NAION development . Other factor associate NAION include high cholesterol , arteriosclerosis , stroke , cardiac intraocular surgery , tobacco use , nocturnal hypotension , blood loss , glaucoma , elevate homocysteine sleep apnea . The association NAION hypertension , high cholesterol diabetes strong individual young 50 year old person . Patients NAION cause ischemia lead swell optic nerve rapidly progress visual loss limited result therapy corticosteroid , brimonidine , levodopa surgery , optic nerve sheath decompression , past . Currently , standard care patient . Although role vascular endothelial growth factor ( VEGF ) NAION establish , ischemic condition may lead VEGF production could cause edema swell . This possibility suggest VEGF may target therapeutic intervention ranibizumab . Ranibizumab demonstrate effect edema vascular permeability . In animal study show concentration- dependent effect blunt vascular permeability induce VEGF . Of 5,000 subject age-related macular degeneration current complete clinical trial , vascular permeability edema decrease use ranibizumab .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Neuropathy , Ischemic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>provide write informed consent 21 year age old new onset , within 14 day , ischemia vision loss Best Corrected Visual Acuity ( BCVA ) 20/40 bad pregnancy lactation proliferative diabetic retinopathy , diabetic macular edema , uveitis , history ocular trauma , severe glaucoma , agerelated macular degeneration . prior concomitant treatment oral steroid within 30 day , participation study investigational drug within 30 day , participation ranibizumab clinical trial , prior treatment intravitreally intravenously Avastin steroid .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>non-arteritic ischemic optic neuropathy</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>naion</keyword>
</DOC>